tiprankstipranks
Advertisement
Advertisement

SKYE Stock Latest News

Skye Bioscience Moves Listing to Nasdaq Capital Market
Company AnnouncementsSkye Bioscience Moves Listing to Nasdaq Capital Market
20d ago
8K
SKYE
Skye Bioscience Expands Authorized Shares After Shareholder Approval
PremiumCompany Announcements
Skye Bioscience Expands Authorized Shares After Shareholder Approval
1M ago
8K
SKYE
Analyst Reiterates Buy on Skye Bioscience, Maintains $20 Price Target on Positive Nimacimab Safety and Efficacy Data
PremiumRatings
Analyst Reiterates Buy on Skye Bioscience, Maintains $20 Price Target on Positive Nimacimab Safety and Efficacy Data
2M ago
SKYE
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity
PremiumCompany Announcements
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity
2M ago
8K
SKYE
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
PremiumThe Fly
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
2M ago
SKYE
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
PremiumThe FlySkye Bioscience reports Q1 EPS (32c), consensus (32c)
2M ago
SKYE
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
Premium
Company Announcements
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
4M ago
8K
SKYE
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
Premium
Ratings
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
4M ago
SKYE
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
PremiumThe Fly
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
4M ago
SKYE
SKYE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SKYE Upcoming Earnings Report: What to Expect?
4M ago
SKYE
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
PremiumRatings
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
5M ago
SKYE
Skye Bioscience Reports Promising Phase 2a Obesity Data
PremiumCompany Announcements
Skye Bioscience Reports Promising Phase 2a Obesity Data
5M ago
8K
SKYE
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
PremiumThe FlySkye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
5M ago
SKYE
Skye Bioscience presents poster on efficacy of Nimacimab
Premium
The Fly
Skye Bioscience presents poster on efficacy of Nimacimab
5M ago
SKYE
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
6M ago
CLB
VTI
Skye Bioscience provides 2026 corporate outlook
PremiumThe Fly
Skye Bioscience provides 2026 corporate outlook
6M ago
SKYE
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
PremiumClass Action
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
6M ago
SKYE
VTI ETF Daily Update — 1/7/26
PremiumMarket News
VTI ETF Daily Update — 1/7/26
6M ago
RPT
VTI
Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
PremiumRatings
Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
6M ago
SKYE
Skye Bioscience, Halozyme enter collaboration, license agreement
PremiumThe FlySkye Bioscience, Halozyme enter collaboration, license agreement
6M ago
HALO
SKYE
Halozyme, Skye Bioscience announce global collaboration, license agreement
Premium
The Fly
Halozyme, Skye Bioscience announce global collaboration, license agreement
6M ago
HALO
SKYE
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
Premium
Company Announcements
Skye Bioscience Collaborates with Halozyme on Nimacimab Delivery
7M ago
8K
SKYE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >